Connect with us

Press Releases

Nanoform Finland PLC, 2020 Half Year Financial Report, 28 August 2020 At 8:10 Am EEST

HELSINKI, Aug. 28, 2020 /PRNewswire/ — Nanoform’s half year financial report January-June 2020: Positive momentum continues to build after successful IPO, near-term business target: “to acquire more new customers in 2020 than in 2019” achieved in July. April-June 2020 in brief: Revenue…

Avatar

Published

on

HELSINKI, Aug. 28, 2020 /PRNewswire/ — Nanoform’s half year financial report January-June 2020: Positive momentum continues to build after successful IPO, near-term business target: “to acquire more new customers in 2020 than in 2019” achieved in July.

April-June 2020 in brief:

  • Revenue grew to EUR 191 thousand, up 28% sequentially from EUR 150 thousand in Q1/2020.
  • Both the gross margin and gross profit increased sequentially, from 68% and EUR 103 thousand in Q1/2020 to 83% and EUR 159 thousand in Q2/2020, respectively.
  • The operating loss was EUR -6.6 million, including EUR -3.1 million costs related to the IPO (operating loss was EUR -1.6 million in Q2/2019).
  • The loss for the period was EUR -6.8 million (EUR -1,7 million in Q2/2019).
  • Basic EPS was EUR -0.14 (EUR -0.04).
  • EUR 79.9 million (gross) was raised in the IPO.
  • The number of employees grew to 55 at the end of Q2/2020 (33).

January-June 2020 in brief:

  • Revenue was EUR 342 thousand, during H1/2019 there were no revenues. The revenues in H1/2020 stemmed from seven different customer projects.
  • Gross margin and profit came in at 77 % and EUR 262 thousand, respectively.
  • The operating loss and the loss for the period were EUR -11.0 million and EUR -11.3 million, respectively.
  • Basic EPS was EUR -0.23 (EUR -0.08).
  • Cash position was EUR 75.2 million on June 30, 2020.

Significant event during H1/2020:

  • Miguel Calado was appointed chairman of the Board of Directors at the AGM, April 7, 2020 after being the vice chairman for a year.
  • In April Nanoform was awarded Good Manufacturing Practices (GMP) status by the Finnish Medicines Agency, FIMEA.
  • In April the Company’s form was changed to a public limited liability company and share capital was increased to EUR 80 thousand.
  • On June 4, EUR 79.9 million (gross) was raised in a successful IPO on Nasdaq First North Premier Growth Markets in Finland and Sweden. The considerably oversubscribed offering attracted strong interest from Global, European, and Nordic investors. Trading started on June 4, 2020.
  • Late June a proof-of-concept contract was signed with a UK Respiratory Biotech company.
  • Late June Nanoform signed (employee contracts with) two experienced commercialization experts in the U.S.
  • During Q2/2020 one new non-GMP line was commissioned, taking our capacity to seven non-GMP lines and one GMP line on the small molecules side.
  • Nanoform appointed Peter Hänninen as General Counsel, starting September 1, 2020.

Significant events after H1/2020:

  • In July Nanoform’s near-term business target to acquire more new customers in 2020 than in 2019 was achieved, when Nanoform signed a contract with a West Coast US Biotech company.
  • On August 6, Nanoform’s Board issued a notice that an extraordinary general meeting (EGM) will convene on September 1, 2020 at 10 am Helsinki time to elect Cynthia Schwalm, a renowned biotechnology and pharmaceutical leader, with experience from top-tier global pharma organizations like J&J, Amgen, Ipsen and Eisai, to the board. Further details on Cynthia Schwalm and the EGM may be found at our web page www.nanoform.com.

Nanoform’s CEO Prof. Edward Hæggström:

The first half of 2020 goes to the history books. The COVID-19 global outbreak that started in China in December 2019, hit Europe and the US hard during March 2020. More or less all global travel between countries was banned and all work that could be done remotely was done from home. Fortunately, our commercial team travelled extensively during 2019 and the beginning of 2020 and introduced our technology to many prospective customers, which made follow-up discussions, negotiations and even signing contracts possible virtually. I’m also pleased that we’ve been able to initiate discussions with entirely new leads during Q2/2020.

I’m very proud that during the first seven months of 2020 we have won more new customers than we did during the entire 2019. I’m confident that the strong commercial momentum will continue, as starting from September 1, we will have doubled the size of our global commercial team after hiring two experienced US-based business development professionals.

Having met our second short-term business target (the first one we met in April, when the Finnish Medicines Agency gave us GMP status) and having successfully listed Nanoform – here I want to take the opportunity to explicitly thank all investors for the faith you have placed in the Nanoform team, the response we got from you during our roadshow was remarkable and energizing – my focus is now on ensuring that Nanoform enters the next stage on its growth trajectory. By that I mean the world of GMP projects supplying material to clinical trials with the long-term vision to help a billion patients. Based on the work done so far I’m confident that we are on track towards achieving our third and fourth short-term business targets, namely starting our first GMP project before year end 2020 and first dosing of nanoformed Active Pharmaceutical Ingredients (API) in humans in 2021.

None of this can be done without our amazing employees and great partners! My sincere THANK YOU to you all for your continued dedication to Nanoform and for the inspiring and innovative work for which we are known. Our journey has only begun, let’s make the coming five years as exciting as the first five have been!

Company near-term business targets for 2020 and 2021 (unchanged):

  • to acquire more new customers in 2020 than in 2019 (achieved in July)
  • to start its first GMP project before year-end 2020
  • to deliver the first dosing of nanoformed APIs in humans in 2021

Company mid-term business targets 2025 (unchanged):

  • to nanoform at least 50 new APIs annually
  • to have in place 25 operating production lines of which 5 to 10 are expected to be GMP production lines
  • over 90 percent gross margin
  • approximately 200 employees
  • to be cash flow positive

Change in equity and outstanding shares during the reported period:

On June 30, 2020 Nanoform had 66,583,772 (37,006,319) shares. Each share entitles to one vote at the General Meeting of Shareholders. On June 30, 2020, the Group’s share capital was EUR 80,000 (EUR 2,500). On June 3, 2020, the Company has issued 20,289,856 and 2,898,551 new shares with directed share issues in connection with the listing. The holders of stock options program 1/2016 exercised their options to subscribe for 1,300,000 shares on April 22, 2020. On June 30, 2020 the Company’s total equity was EUR 69.47 million (EUR 12.18 million).

Nanoform Group’s key figures, Financial KPI’s:

         

EUR thousand

4-6/2020

4-6/2019 

1-6/2020

1-6/2019 

 1-12/2019

                                   

                                   

Revenue

 

191


 

342


 

49

                                   

Gross profit

 

159

 

-90

 

262

 

-145

 

 

-323

                                   

EBITDA

 

-6,348

 

-1,488

 

-10,485

 

-2,488

 

 

-6,900

                                   

Operating loss

 

-6,622

 

-1,579

 

-10,987

 

-2,663

 

 

-7,344

                                   

Loss for the period

 

-6,758

 

-1,647

 

-11,345

 

-2,791

 

 

-7,554

                                   

Basic EPS (EUR)

 

-0.14

 

-0.04

 

-0.23

 

-0.08

 

 

-0.19

                                   

Net debt

 

-69,751

 

-7,958

 

-69,751

 

-7,958

 

 

-3,640

                                   

Net debt excluding lease liabilities

 

-74,101

 

-9,748

 

-74,101

 

-9,748

 

 

-6,626

                                   

Investments in property, plant and equipment

 

-514

 

-360

 

-838

 

-467

 

 

-1,804

                                   

Operative free cash flow

 

-6,863

 

-1,848

 

-11,322

 

-2,955

 

 

-8,704

                                   

Cash and cash equivalents (end of period)

 

75,155

 

10,394

 

75,155

 

10,394

 

 

7,303

Nanoform Group’s key figures, Operational KPI’s:

        

EUR thousand

4-6/2020

4-6/2019

 1-6/2020 

1-6/2019

1-12/2019

                                   

                                   

Number of new projects started during the period







                                   

Non-GMP

 

1

 

0

 

5

 

0


 

2

                                   

GMP

 

0

 

0

 

0

 

0


 

0






                                   

Number of lines (end of the period)






                                   

Non-GMP

 

7

 

4

 

7

 

0


 

4

                                   

GMP

 

1

 

0

 

1

 

0


 

0







                                   

Number of employees (end of the period)

 

55

 

33

 

55

 

33


 

43

Nanoform’s complete half year financial report January-June 2020 can also be found at: https://nanoform.com/en/financial-reports-and-presentations/

Telephone conference for analysts, investors and media:

Nanoform H1/2020 Conference Call Friday August 28th 09:00 EEST (08:00 CEST)

Nanoform will hold a conference call in connection with the Q2/2020 report. Nanoform is represented by CEO Edward Hæggström, CFO Albert Hæggström, CCO Christian Jones, CBO Gonçalo Andrade and Director of Investor Relations Henri von Haartman.

Please call 5-10 minutes prior to the event for a prompt start. Participants Dial in (Access Code: 793554):

Finland (Local) 075 3252542

Denmark (Local) 89 87 50 45

Sweden 0200 123 717

Sweden (Local) 010 884 80 16

Denmark 80 82 00 35

Norway (Local) 815 03 308

United Kingdom 0800 640 6441

United Kingdom (Local) 020 3936 2999

Switzerland (Local) 022 518 90 26

US and all other locations +44 20 3936 2999

Viewing the presentation: www.incommuk.com/ customers/nanoformcall (Access Code: 793554)

For further information, please contact:

Albert Hæggström, CFO

[email protected] / +358 29 370 0150

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

[email protected] / +46 7686 650 11

Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming services. The Company’s patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform’s unique technology provides novel opportunities in many value-enhancing drug delivery applications.For more information please visit http://www.nanoform.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nanoform/r/nanoform-finland-plc–2020-half-year-financial-report–28-august-2020-at-8-10-am-eest,c3182930

The following files are available for download:

SOURCE Nanoform

Source: https://www.prnewswire.com:443/news-releases/nanoform-finland-plc-2020-half-year-financial-report-28-august-2020-at-810-am-eest-301120216.html

Press Releases

Jubilant Therapeutics kündigt Präsentation auf virtueller ASH-Jahrestagung 2020 an

BEDMINSTER, N. J., 25. November 2020 /PRNewswire/ — Jubilant Therapeutics Inc., ein Biopharma-Unternehmen, das kleine Molekülmodulatoren entwickelt, um medizinische Bedürfnisse in der Onkologie und bei Autoimmunkrankheiten zu erfüllen, hat heute bekannt gegeben, dass eine Kurzdarstellung…

Avatar

Published

on

BEDMINSTER, N. J., 25. November 2020 /PRNewswire/ — Jubilant Therapeutics Inc., ein Biopharma-Unternehmen, das kleine Molekülmodulatoren entwickelt, um medizinische Bedürfnisse in der Onkologie und bei Autoimmunkrankheiten zu erfüllen, hat heute bekannt gegeben, dass eine Kurzdarstellung zu seinem LSD1/HDAC6-Doppelhemmer JBI-802 zur Präsentation auf der 62. Jahrestagung der American Society of Hematology (ASH), die von 5. bis 8. Dezember 2020 in virtueller Form stattfindet, zugelassen wurde.

„Wir freuen uns darauf, auf der virtuellen ASH-Jahrestagung 2020 über unseren neuartigen wirksamen und selektiven LSD1/HDAC6-Doppelhemmer für die Krebsbehandlung zu sprechen”, erklärte Syed Kazmi, Präsident und Chief Executive Officer von Jubilant Therapeutics. „Unsere Arbeit, JBI-802 als potenzielles, differenziertes Therapeutikum für die Behandlung ausgewählter hämatologischer und solider Tumoren mit spezifischen Gensignaturen in die klinische Praxis zu bringen, schreitet voran, und wir gehen davon aus, dass wir in der zweiten Hälfte des nächsten Jahres erste Studien am Menschen einleiten können.”

Die Kurzdarstellung ist derzeit auf der ASH-Konferenz-Website verfügbar und lautet folgendermaßen:

Titel: Novel Dual Inhibitor of LSD1-HDAC6/8 for Treatment of Cancer (dt. Neuartiger LSD1-HDAC6/8-Doppelhemmer zur Behandlung von Krebs)

Datum: Montag, 7. Dezember 2020

Session: 802. Chemical Biology and Experimental Therapeutics: Poster III (Chemische Biologie und experimentelle Therapeutika: Poster III)

Kurzdarstellung: 3378

Vortragende(r): Dhanalakshmi Sivanandhan, Ph.D., stellvertretender Vizepräsident und Leiter Biologie bei Jubilant Therapeutics Inc.

Informationen zu Jubilant Therapeutics 

Jubilant Therapeutics Inc. ist ein patientenorientiertes biopharmazeutisches Unternehmen, das wirksame und selektive kleine Molekülmodulatoren entwickelt, um medizinische Bedürfnisse in der Onkologie und bei Autoimmunerkrankungen zu erfüllen. Seine fortschrittliche Forschungsstrategie integriert strukturbasiertes Design und Berechnungsalgorithmen, um neuartige, präzise Therapeutika zu entdecken und zu entwickeln, die sowohl gegen erste Ziele ihrer Art als auch gegen validierte, aber hartnäckige Ziele in genetisch definierten Patientenpopulationen gerichtet sind. Die unternehmerisch denkende Führung und die wissenschaftlichen Teams des Unternehmens streben nach Schnelligkeit und Effizienz, indem sie ein Geschäftsmodell anwenden, das die bewährten und synergetischen Fähigkeiten der Wertschöpfungskette und der gemeinsamen Dienstleistungen von Jubilant Life Sciences Limited nutzt. Jubilant Therapeutics hat seinen Hauptsitz in den USA und wird von weltweit anerkannten Meinungsführern und Mitgliedern des Wissenschaftlichen Beirats geleitet. Weitere Information finden Sie auf www.jubilanttx.com oder folgen Sie uns auf Twitter @JubilantTx oder LinkedIn.

Logo: https://mma.prnewswire.com/media/1064788/Jubilant_Therapeutics_Logo.jpg

SOURCE Jubilant Therapeutics Inc.

Source: https://www.prnewswire.com:443/news-releases/jubilant-therapeutics-kundigt-prasentation-auf-virtueller-ash-jahrestagung-2020-an-825840214.html

Continue Reading

Press Releases

ROSEN, A TOP RANKED LAW FIRM, Reminds Raytheon Technologies Corporation f/k/a Raytheon Company Investors of Important Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RTX, RTN

NEW YORK, Nov. 24, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Raytheon Technologies Corporation f/k/a Raytheon Company (NYSE: RTX, RTN) between February 10, 2016 and October 27, 2020, inclusive (the “Class Period”), of…

Avatar

Published

on

NEW YORK, Nov. 24, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Raytheon Technologies Corporation f/k/a Raytheon Company (NYSE: RTX, RTN) between February 10, 2016 and October 27, 2020, inclusive (the “Class Period”), of the important December 29, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Raytheon investors under the federal securities laws.

To join the Raytheon class action, go to http://www.rosenlegal.com/cases-register-1975.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Raytheon had inadequate disclosure controls and procedures and internal control over financial reporting; (2) Raytheon had faulty financial accounting; (3) as a result, Raytheon misreported its costs regarding Raytheon’s Missiles & Defense business since 2009; (4) as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; (5) as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice (“DOJ”); and (6) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1975.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY  10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

SOURCE Rosen Law Firm, P.A.

Related Links

www.rosenlegal.com

Source: https://www.prnewswire.com:443/news-releases/rosen-a-top-ranked-law-firm-reminds-raytheon-technologies-corporation-fka-raytheon-company-investors-of-important-deadline-in-securities-class-action-first-filed-by-the-firm-encourages-investors-with-losses-in-excess-of-100k-301180237.html

Continue Reading

Press Releases

SHIELD annonce DeviceSHIELD pour protéger les petites entreprises contre la cyberfraude pendant la pandémie de COVID-19

DeviceSHIELD fournira gratuitement des renseignements sur les risques à 90 % des entreprises en ligne pour aider à lutter contre la fraude et à prévenir des pertes financières moyennes de 200 000 $ en raison de cyberattaques¹ MENLO PARK, Californie, 25 novembre 2020 /PRNewswire/ –…

Avatar

Published

on

DeviceSHIELD fournira gratuitement des renseignements sur les risques à 90 % des entreprises en ligne pour aider à lutter contre la fraude et à prévenir des pertes financières moyennes de 200 000 $ en raison de cyberattaques¹ 

MENLO PARK, Californie, 25 novembre 2020 /PRNewswire/ — SHIELD, la plus importante entreprise de cybersécurité au monde spécialisée dans la cyberfraude et la vérification de l’identité, a lancé aujourd’hui DeviceSHIELD. Il s’agit d’une solution contre la cyberfraude conçue spécialement pour lutter contre l’augmentation des attaques frauduleuses à l’encontre des entreprises en ligne pendant la pandémie de COVID-19. La solution fournit des renseignements utiles en temps réel pour repérer les faux dispositifs et protéger les entreprises contre les fraudeurs, les atteintes à la réputation et les transactions frauduleuses.

Pendant la pandémie de COVID-19, la cyberfraude est devenue l’activité criminelle qui connaît la croissance la plus rapide, ce qui expose les entreprises et les consommateurs à des risques accrus. Aujourd’hui, les consommateurs effectuent davantage de transactions numériques et utilisent de plus en plus d’applications en ligne. SHIELD a cerné plusieurs secteurs clés plus touchés par la cyberfraude depuis le début de la pandémie de COVID-19. Notamment les services à la demande comme la livraison de nourriture et la réservation de voiture avec chauffeur, le commerce électronique et les plateformes de marché, les jeux en ligne, les porte-monnaie électroniques, la fidélisation et les offres de « cashback », les services bancaires en ligne et le divertissement.

Au cours de la dernière année, les outils qu’utilisent les pirates informatiques se sont également perfectionnés. Les fraudeurs utilisent maintenant des émulateurs, des cloneurs d’applications, des réseaux privés virtuels et des systèmes de spoofing du système de positionnement mondial (GPS) des appareils mobiles pour commettre des fraudes.

« Plus il y a de transactions en ligne, plus les vulnérabilités à la cyberfraude sont importantes, et cela est plus que jamais d’actualité dans le contexte de la COVID-19, a déclaré Justin Lie, président-directeur général de SHIELD. Près de la moitié (43 %) des attaques en ligne visent maintenant les petites entreprises, et seulement 14 % d’entre elles sont activement prêtes à se défendre2. Nous avons créé une technologie pour protéger les secteurs en ligne qui, selon nous, sont les plus touchés par la COVID-19. Toutefois, toutes les entreprises qui comptent moins de 100 000 utilisateurs actifs par mois la recevront gratuitement, ce qui équivaut à environ 90 % de toutes les entreprises en ligne. »

SHIELD s’est engagé à lutter contre les répercussions économiques découlant de la pandémie de COVID-19. Le nombre de fraudeurs qui dissimulent l’identité en ligne de leurs appareils a augmenté à un rythme inattendu pendant la pandémie, ce qui rend les petites et moyennes entreprises particulièrement vulnérables. Les solutions conventionnelles de lutte contre la cyberfraude ont tendance à n’analyser que les attributs de surface et sont particulièrement inefficaces avec les appareils mobiles, ne permettant pas d’éliminer les menaces les plus subtiles et les plus furtives.

DeviceSHIELD est actuellement la seule technologie qui utilise l’ADN d’un dispositif pour identifier les utilisateurs malveillants, ce qui lui permet de détecter les fraudes avec une précision et une cohérence inégalées. Déployé en quelques minutes, DeviceSHIELD analyse des milliers d’attributs pour identifier un appareil, peu importe le nombre de fois dont il change son apparence, et indique exactement quels outils malveillants sont utilisés. La solution possède une fonction unique appelée SHIELD Sentinel qui lui permet de dresser continuellement le profil du risque tout au long d’une session utilisateur, une autre première dans le secteur. Elle s’appuie également sur le réseau de SHIELD, connu sous le nom de Global Intelligence Network, qui compte plus de sept milliards d’appareils et 500 millions d’utilisateurs sur six continents. Elle est donc en mesure de protéger un dispositif contre de nouveaux types inconnus de fraudes de manière proactive.

GGV Capital, Future Shape de Tony Fadell, Temasek, Wavemaker Partners et Tao Zhang sont des investisseurs de SHIELD. Les solutions de SHIELD sont actuellement utilisées par des entreprises mondiales comme Razer, Alibaba, Scalefast, Yamibuy, PayMaya et Sea Group pour lutter contre la cyberfraude.

À propos de SHIELD 

SHIELD est la première entreprise de cybersécurité au monde à se spécialiser dans les solutions de cyberfraude et de vérification d’identité. Les solutions de SHIELD vont de la prévention de la fraude à la sécurité du réseau, en passant par le renseignement sur le crédit et la vérification de l’identité. Possédant des bureaux dans le monde entier, SHIELD jouit de la confiance de superapplications, de plateformes de commerce électronique et de services de réservation de voiture avec chauffeur de premier plan partout dans le monde. Grâce à la reconnaissance des tendances et au profilage continu des risques, SHIELD fournit des renseignements utiles sur les dispositifs et des signaux en temps réel qui permettent aux entreprises d’évoluer en toute sécurité.

Pour en savoir plus, consultez le site https://shield.com/solutions/deviceshield.

Contact : 

Demande de renseignements des médias
Simone Jackenthal
Trident DMG
+ 1 (202) 923-5296
[email protected] 

1 Hiscox, « Hiscox Cyber Readiness Report 2019 (Rapport 2019 d’Hiscox sur la cyberpréparation) »
2
 CNBC, « Cyberattacks now cost companies $200,000 on average, putting many out of business (Les cyberattaques coûtent aujourd’hui 200 000 dollars en moyenne aux entreprises, ce qui en force beaucoup à mettre la clé sous la porte »

Logo – https://mma.prnewswire.com/media/1341295/SHIELD_tagline_Logo.jpg

Related Links

https://shield.com

SOURCE SHIELD

Source: https://www.prnewswire.com:443/news-releases/shield-annonce-deviceshield-pour-proteger-les-petites-entreprises-contre-la-cyberfraude-pendant-la-pandemie-de-covid-19-878635979.html

Continue Reading
Blockchain3 hours ago

The North American Bitcoin Conference Returns

Blockchain3 hours ago

12 Blockchain Industry Experts Offer Predictions For 2020

Blockchain3 hours ago

Bitcoin’s Halving May Not Pump Price Like Last Time – Here’s Why It Doesn’t Matter

Blockchain3 hours ago

What Are “Crypto/Digital Assets” and How Can They Be Taxed?

Blockchain3 hours ago

The Most Common Types Of Cryptocurrency Scams in 2020

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Venture Capital3 hours ago

Venture Capital3 hours ago

Venture Capital3 hours ago

Venture Capital3 hours ago

Venture Capital3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Startup3 hours ago

New Report Reveals Key Insights on the Future of Work in Latin America

Venture Capital3 hours ago

Ripple’s XRP surges 70% as Bitcoin craze sends investors flocking to smaller cryptocurrencies

Blockchain3 hours ago

Bison Trails launches QT protocol to help developers build on Libra

Blockchain3 hours ago

Stellar Lumens doubles in price following upgrade

Press Releases3 hours ago

Jubilant Therapeutics kündigt Präsentation auf virtueller ASH-Jahrestagung 2020 an

Startup3 hours ago

Mobile-only bank N26 launches N26 Smart, a new premium digital bank account for just €4.90 a month

Press Releases4 hours ago

ROSEN, A TOP RANKED LAW FIRM, Reminds Raytheon Technologies Corporation f/k/a Raytheon Company Investors of Important Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RTX, RTN

Press Releases4 hours ago

SHIELD annonce DeviceSHIELD pour protéger les petites entreprises contre la cyberfraude pendant la pandémie de COVID-19

Press Releases4 hours ago

The “Haday Cup” 2020 Chinese Cuisine World Championship concludes in west China’s Chongqing Banan

Blockchain4 hours ago

Grayscale Bitcoin Trust (GBTC) Surges Past $10 Billion Assets Under Management

Trending